DWTX
Dogwood Therapeutics, Inc. NASDAQ Listed Dec 17, 2020$1.65
After hrs
$1.70
+2.77%
Mkt Cap $3.2M
52w Low $1.28
4.5% of range
52w High $9.50
50d MA $2.23
200d MA $4.26
P/E (TTM)
-0.3x
EV/EBITDA
-1.0x
P/B
0.2x
Debt/Equity
0.0x
ROE
-45.7%
P/FCF
-2.2x
RSI (14)
—
ATR (14)
—
Beta
2.07
50d MA
$2.23
200d MA
$4.26
Avg Volume
81.0K
About
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | AMC | -0.86 | -0.26 | +69.8% | 2.97 | -2.4% | -8.4% | +1.0% | -6.4% | -12.8% | -22.2% | — |
| Nov 6, 2025 | AMC | -1.23 | -8.20 | -566.7% | 5.20 | +0.6% | +1.2% | +6.9% | +8.5% | +12.1% | +5.0% | — |
| Aug 13, 2025 | AMC | -1.26 | -1.99 | -57.9% | 4.80 | +1.9% | +2.5% | +2.7% | +10.4% | +0.2% | +1.2% | — |
| May 8, 2025 | AMC | -0.77 | -4.21 | -446.8% | 4.56 | -2.0% | +0.0% | +4.8% | +6.4% | +6.4% | +20.4% | — |
| Feb 26, 2025 | AMC | -1.36 | -5.90 | -333.6% | 5.12 | -2.0% | -8.0% | -6.4% | -16.2% | -18.9% | -13.1% | — |
| Nov 7, 2024 | AMC | -1.18 | -2.05 | -73.7% | 4.45 | +0.7% | -3.4% | -23.1% | -22.2% | -33.3% | -28.1% | — |
| Aug 8, 2024 | AMC | -0.07 | -0.05 | +28.6% | 4.47 | +4.0% | -2.0% | -6.5% | +0.7% | -1.6% | +5.6% | — |
| May 9, 2024 | AMC | -0.08 | -0.07 | +12.5% | 9.32 | -1.5% | -4.7% | -5.0% | +2.5% | +9.2% | +3.5% | — |
| Dec 31, 2023 | AMC | -1.75 | -1.43 | +18.2% | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | -2.25 | -1.62 | +28.1% | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.38 | $1.35 | -2.2% | -2.9% | -2.2% | -2.2% | +3.6% | +5.8% |
| Feb 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.91 | $3.01 | +3.4% | +0.7% | -5.5% | -3.8% | -1.4% | -5.2% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $2.86 | -1.4% | -3.8% | +1.0% | +4.5% | +6.2% | +9.3% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.91 | $7.88 | -0.4% | -2.7% | -10.6% | -18.8% | -19.0% | -15.4% |
| Apr 23 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $5.46 | $5.72 | +4.8% | +7.5% | +3.7% | +1.3% | +2.4% | -0.9% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
DWTX's development-stage pain/neuropathy pipeline targets a large market with significant unmet need, but investors should monitor clinical progress closely given the company has no revenue and high cash burn typical of early-stage biotech.
Mar 26
8-K
Unknown — 8-K Filing
Dogwood Therapeutics reported full-year 2025 results as a development-stage biotech with no revenue, making cash burn and financing runway critical metrics for investors evaluating survival probability and future dilution risk.
Mar 18
8-K
Unknown — 8-K Filing
DWTX shareholders approved postponing a special meeting, likely signaling the company needs more time to finalize a major transaction, which could delay expected announcements and create near-term uncertainty for investors.
Mar 12
Data updated apr 25, 2026 6:06am
· Source: massive.com